Oncolytics Biotech Inc. (ONCY)
USD 0.55
(0.0%)
USD 0.55
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 423 Thousand CAD | 13.4% |
| 2022 | 373 Thousand CAD | -43.03% |
| 2021 | 654.75 Thousand CAD | 62.85% |
| 2020 | 402.05 Thousand CAD | -20.58% |
| 2019 | 506.27 Thousand CAD | 0.0% |
| 2018 | - CAD | 0.0% |
| 2017 | - CAD | 0.0% |
| 2016 | - CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| 2008 | - CAD | 0.0% |
| 2007 | - CAD | -100.0% |
| 2006 | 150 Thousand CAD | 0.0% |
| 2005 | 150 Thousand CAD | 0.0% |
| 2004 | 150 Thousand CAD | 0.0% |
| 2003 | 150 Thousand CAD | 0.0% |
| 2002 | 150 Thousand CAD | 0.0% |
| 2001 | 150 Thousand CAD | 0.0% |
| 2000 | 150 Thousand CAD | 0.0% |
| 1999 | 150 Thousand CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.11 Million CAD | -0.98% |
| 2024 Q1 | 1.12 Million CAD | 166.43% |
| 2023 Q2 | 479 Thousand CAD | -15.52% |
| 2023 Q1 | 567 Thousand USD | 52.01% |
| 2023 FY | 423 Thousand CAD | 13.4% |
| 2023 Q3 | 514 Thousand CAD | 7.31% |
| 2023 Q4 | 423 Thousand CAD | -17.7% |
| 2022 FY | 373 Thousand CAD | -43.03% |
| 2022 Q2 | 522.44 Thousand CAD | -10.56% |
| 2022 Q4 | 373 Thousand CAD | -19.05% |
| 2022 Q3 | 460.78 Thousand CAD | -11.8% |
| 2022 Q1 | 584.12 Thousand CAD | -10.79% |
| 2021 FY | 654.75 Thousand CAD | 62.85% |
| 2021 Q3 | 710.74 Thousand CAD | -4.54% |
| 2021 Q1 | 624.33 Thousand CAD | 55.28% |
| 2021 Q4 | 654.75 Thousand CAD | -7.88% |
| 2021 Q2 | 744.5 Thousand CAD | 19.25% |
| 2020 Q2 | 325.17 Thousand CAD | -25.63% |
| 2020 FY | 402.05 Thousand CAD | -20.58% |
| 2020 Q4 | 402.05 Thousand CAD | -22.16% |
| 2020 Q1 | 437.21 Thousand CAD | -13.64% |
| 2020 Q3 | 516.51 Thousand CAD | 58.84% |
| 2019 Q2 | 689.75 Thousand CAD | -11.45% |
| 2019 Q4 | 506.27 Thousand CAD | -16.2% |
| 2019 Q3 | 604.13 Thousand CAD | -12.41% |
| 2019 FY | 506.27 Thousand CAD | 0.0% |
| 2019 Q1 | 778.94 Thousand CAD | 0.0% |
| 2018 Q1 | - CAD | 0.0% |
| 2018 Q4 | - CAD | 0.0% |
| 2018 FY | - CAD | 0.0% |
| 2018 Q3 | - CAD | 0.0% |
| 2018 Q2 | - CAD | 0.0% |
| 2017 FY | - CAD | 0.0% |
| 2017 Q3 | - CAD | 0.0% |
| 2017 Q4 | - CAD | 0.0% |
| 2017 Q1 | - CAD | 0.0% |
| 2017 Q2 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2009 Q1 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q3 | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2008 Q4 | - CAD | 0.0% |
| 2008 FY | - CAD | 0.0% |
| 2008 Q3 | - CAD | 0.0% |
| 2008 Q2 | - CAD | 0.0% |
| 2008 Q1 | - CAD | 0.0% |
| 2007 Q4 | - CAD | 0.0% |
| 2007 Q2 | - CAD | 0.0% |
| 2007 FY | - CAD | -100.0% |
| 2007 Q3 | - CAD | 0.0% |
| 2007 Q1 | - CAD | -100.0% |
| 2006 FY | 150 Thousand CAD | 0.0% |
| 2006 Q2 | 150 Thousand CAD | 0.0% |
| 2006 Q3 | 150 Thousand CAD | 0.0% |
| 2006 Q4 | 150 Thousand CAD | 0.0% |
| 2006 Q1 | 150 Thousand CAD | 0.0% |
| 2005 Q4 | 150 Thousand CAD | -13.9% |
| 2005 Q1 | 150 Thousand CAD | 0.0% |
| 2005 Q2 | 150 Thousand CAD | 0.0% |
| 2005 Q3 | 174.21 Thousand CAD | 16.14% |
| 2005 FY | 150 Thousand CAD | 0.0% |
| 2004 Q4 | 150 Thousand CAD | 0.0% |
| 2004 Q2 | 150 Thousand CAD | 0.0% |
| 2004 Q3 | 150 Thousand CAD | 0.0% |
| 2004 FY | 150 Thousand CAD | 0.0% |
| 2004 Q1 | 150 Thousand CAD | 0.0% |
| 2003 Q4 | 150 Thousand CAD | 0.0% |
| 2003 FY | 150 Thousand CAD | 0.0% |
| 2003 Q1 | 150 Thousand CAD | 0.0% |
| 2003 Q2 | 150 Thousand CAD | 0.0% |
| 2003 Q3 | 150 Thousand CAD | 0.0% |
| 2002 Q1 | 150 Thousand CAD | 0.0% |
| 2002 Q2 | 150 Thousand CAD | 0.0% |
| 2002 Q3 | 161.9 Thousand CAD | 7.94% |
| 2002 FY | 150 Thousand CAD | 0.0% |
| 2002 Q4 | 150 Thousand CAD | -7.35% |
| 2001 Q1 | - CAD | -100.0% |
| 2001 Q4 | 150 Thousand CAD | 0.0% |
| 2001 Q3 | 150 Thousand CAD | 0.0% |
| 2001 FY | 150 Thousand CAD | 0.0% |
| 2001 Q2 | 150 Thousand CAD | 0.0% |
| 2000 Q4 | 150 Thousand CAD | 0.0% |
| 2000 Q3 | 150 Thousand CAD | 0.0% |
| 2000 Q2 | 150 Thousand CAD | 0.0% |
| 2000 Q1 | 150 Thousand CAD | 0.0% |
| 2000 FY | 150 Thousand CAD | 0.0% |
| 1999 FY | 150 Thousand CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Absci Corporation | 15.95 Million USD | 97.349% |
| Adaptive Biotechnologies Corporation | 229.43 Million USD | 99.816% |
| Alnylam Pharmaceuticals, Inc. | 2.68 Billion USD | 99.984% |
| Alzamend Neuro, Inc. | 300.71 Thousand USD | -40.665% |
| Apollomics, Inc. | 4.66 Million USD | 90.925% |
| 180 Life Sciences Corp. | 1.32 Million USD | 67.956% |
| Atossa Therapeutics, Inc. | - USD | -Infinity% |
| Bicycle Therapeutics plc | 44.95 Million USD | 99.059% |
| Barinthus Biotherapeutics plc | 12.97 Million USD | 96.74% |
| BioXcel Therapeutics, Inc. | 101.38 Million USD | 99.583% |
| CASI Pharmaceuticals, Inc. | 21.23 Million USD | 98.008% |
| Chimerix, Inc. | 2.14 Million USD | 80.271% |
| CRISPR Therapeutics AG | 238.63 Million USD | 99.823% |
| Contineum Therapeutics, Inc. Class A Common Stock | 193.19 Million USD | 99.781% |
| EyePoint Pharmaceuticals, Inc. | 5.46 Million USD | 92.265% |
| Fortress Biotech, Inc. | 88.59 Million USD | 99.523% |
| Fortress Biotech, Inc. | 88.59 Million USD | 99.523% |
| Gritstone bio, Inc. | 104.77 Million USD | 99.596% |
| Allakos Inc. | 41.46 Million USD | 98.98% |
| Boundless Bio, Inc. Common Stock | 2.19 Million USD | 80.729% |
| Cara Therapeutics, Inc. | 43.16 Million USD | 99.02% |
| Cytokinetics, Incorporated | 755.77 Million USD | 99.944% |
| enGene Holdings Inc. Common Stock | 9.77 Million USD | 95.674% |
| Innoviva, Inc. | 449.07 Million USD | 99.906% |
| Hoth Therapeutics, Inc. | 55.16 Thousand USD | -666.791% |
| NLS Pharmaceutics AG | 1.63 Million USD | 74.109% |
| RAPT Therapeutics, Inc. | 6.9 Million USD | 93.875% |
| Salarius Pharmaceuticals, Inc. | 289.64 Thousand USD | -46.042% |
| Terns Pharmaceuticals, Inc. | 603 Thousand USD | 29.851% |
| Vigil Neuroscience, Inc. | 13.85 Million USD | 96.946% |
| ImmuCell Corporation | 11.96 Million USD | 96.466% |
| IDEAYA Biosciences, Inc. | 2.87 Million USD | 85.272% |
| Incyte Corporation | 38.28 Million USD | 98.895% |
| Inovio Pharmaceuticals, Inc. | 30.2 Million USD | 98.6% |
| Lexaria Bioscience Corp. | 163.96 Thousand USD | -157.979% |
| Mustang Bio, Inc. | 2.49 Million USD | 83.066% |
| MiMedx Group, Inc. | 48.09 Million USD | 99.121% |
| MEI Pharma, Inc. | - USD | -Infinity% |
| MacroGenics, Inc. | 33.97 Million USD | 98.755% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Mereo BioPharma Group plc | 5.95 Million USD | 92.893% |
| Marker Therapeutics, Inc. | - USD | -Infinity% |
| Marinus Pharmaceuticals, Inc. | 110.35 Million USD | 99.617% |
| Maravai LifeSciences Holdings, Inc. | 610.96 Million USD | 99.931% |
| Minerva Neurosciences, Inc. | 82.01 Million USD | 99.484% |
| NeuroBo Pharmaceuticals, Inc. | 203 Thousand USD | -108.374% |
| NeuroSense Therapeutics Ltd. | 142 Thousand USD | -197.887% |
| NextCure, Inc. | 6.6 Million USD | 93.596% |
| Orchestra BioMed Holdings, Inc. | 1.68 Million USD | 74.926% |
| Ocuphire Pharma, Inc. | - USD | -Infinity% |
| Onconetix, Inc. | 9.88 Million USD | 95.721% |
| Oncternal Therapeutics, Inc. | 318 Thousand USD | -33.019% |
| Opthea Limited | 200.62 Million USD | 99.789% |
| Ovid Therapeutics Inc. | 46 Million USD | 99.08% |
| Psyence Biomedical Ltd. | 7.65 Million USD | 94.476% |
| PDS Biotechnology Corporation | 23.85 Million USD | 98.227% |
| Precigen, Inc. | 7.09 Million USD | 94.04% |
| Pieris Pharmaceuticals, Inc. | - USD | -Infinity% |
| Prime Medicine, Inc. | 13.63 Million USD | 96.897% |
| PureTech Health plc | 25.51 Million USD | 98.342% |
| Rocket Pharmaceuticals, Inc. | 25.04 Million USD | 98.311% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.984% |
| Replimune Group, Inc. | 75.86 Million USD | 99.442% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Rigel Pharmaceuticals, Inc. | 60.57 Million USD | 99.302% |
| TransCode Therapeutics, Inc. | 450.57 Thousand USD | 6.119% |
| Revolution Medicines, Inc. Warrant | 87.94 Million USD | 99.519% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Sesen Bio, Inc. | - USD | -Infinity% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | 98.89% |
| Solid Biosciences Inc. | 26.26 Million USD | 98.389% |
| Syndax Pharmaceuticals, Inc. | 1.63 Million USD | 74.128% |
| SciSparc Ltd. | 76 Thousand USD | -456.579% |
| Sutro Biopharma, Inc. | 182.74 Million USD | 99.769% |
| TG Therapeutics, Inc. | 110.79 Million USD | 99.618% |
| Tonix Pharmaceuticals Holding Corp. | 9.81 Million USD | 95.689% |
| Titan Pharmaceuticals, Inc. | 565 Thousand USD | 25.133% |
| Travere Therapeutics, Inc. | 404.78 Million USD | 99.895% |
| UroGen Pharma Ltd. | 100.21 Million USD | 99.578% |
| Verrica Pharmaceuticals Inc. | 45.51 Million USD | 99.071% |
| XOMA Corporation | 124.45 Million USD | 99.66% |
| Zentalis Pharmaceuticals, Inc. | 45.77 Million USD | 99.076% |
| AbCellera Biologics Inc. | 77.38 Million USD | 99.453% |
| Longboard Pharmaceuticals, Inc. | 475 Thousand USD | 10.947% |
| Cassava Sciences, Inc. | - USD | -Infinity% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | 97.975% |
| Precision BioSciences, Inc. | 31.26 Million USD | 98.647% |
| Dyadic International, Inc. | 136.92 Thousand USD | -208.919% |
| Intensity Therapeutics, Inc. | 158 Thousand USD | -167.722% |
| Eton Pharmaceuticals, Inc. | 5.45 Million USD | 92.246% |
| VYNE Therapeutics Inc. | 214 Thousand USD | -97.664% |
| Tenaya Therapeutics, Inc. | 12.42 Million USD | 96.595% |
| IGM Biosciences, Inc. | 40.5 Million USD | 98.956% |
| X4 Pharmaceuticals, Inc. | 58.28 Million USD | 99.274% |
| Acelyrin, Inc. | 1.19 Million USD | 64.573% |
| Abeona Therapeutics Inc. | 5.4 Million USD | 92.167% |
| Ligand Pharmaceuticals Incorporated | 6.16 Million USD | 93.139% |
| Inhibikase Therapeutics, Inc. | 622 Thousand USD | 31.994% |
| Arcturus Therapeutics Holdings Inc. | 30.21 Million USD | 98.6% |
| Syros Pharmaceuticals, Inc. | 62.07 Million USD | 99.319% |
| Senti Biosciences, Inc. | 37.66 Million USD | 98.877% |
| Mesoblast Limited | 118.92 Million USD | 99.644% |
| Kymera Therapeutics, Inc. | 84.67 Million USD | 99.5% |
| ChromaDex Corporation | 3.27 Million USD | 87.092% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Akebia Therapeutics, Inc. | 104.18 Million USD | 99.594% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Seer, Inc. | 28.25 Million USD | 98.503% |
| Xeris Biopharma Holdings, Inc. | 229.19 Million USD | 99.815% |
| Novavax, Inc. | 280.63 Million USD | 99.849% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| Fate Therapeutics, Inc. | 103.53 Million USD | 99.591% |
| Checkpoint Therapeutics, Inc. | - USD | -Infinity% |
| Lyell Immunopharma, Inc. | 63.16 Million USD | 99.33% |
| Celcuity Inc. | 37.44 Million USD | 98.87% |
| ContextLogic Inc. | 6 Million USD | 92.95% |
| Phathom Pharmaceuticals, Inc. | 139.03 Million USD | 99.696% |
| HOOKIPA Pharma Inc. | 6.55 Million USD | 93.551% |
| Jazz Pharmaceuticals plc | 5.79 Billion USD | 99.993% |
| Amarin Corporation plc | 8.73 Million USD | 95.159% |
| AnaptysBio, Inc. | 17.81 Million USD | 97.625% |
| Aptevo Therapeutics Inc. | 5.39 Million USD | 92.162% |
| Aptorum Group Limited | 3.36 Million USD | 87.42% |
| Cartesian Therapeutics, Inc. | 10.95 Million USD | 96.139% |
| Arrowhead Pharmaceuticals, Inc. | 115.17 Million USD | 99.633% |
| Ardelyx, Inc. | 55.98 Million USD | 99.244% |
| Celularity Inc. | 65.41 Million USD | 99.353% |
| Omeros Corporation | 338.28 Million USD | 99.875% |
| Humacyte, Inc. | 58.1 Million USD | 99.272% |
| Immunocore Holdings plc | 84.03 Million USD | 99.497% |
| IO Biotech, Inc. | 2.49 Million USD | 83.039% |
| GT Biopharma, Inc. | 58 Thousand USD | -629.31% |
| Cabaletta Bio, Inc. | 5.01 Million USD | 91.57% |
| Summit Therapeutics Inc. | 106.09 Million USD | 99.601% |
| Alaunos Therapeutics, Inc. | - USD | -Infinity% |
| Pulmatrix, Inc. | 8.75 Million USD | 95.169% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 99.633% |
| Evogene Ltd. | 1.13 Million USD | 62.83% |
| CorMedix Inc. | 667.63 Thousand USD | 36.642% |
| BioLineRx Ltd. | 11.59 Million USD | 96.351% |
| VistaGen Therapeutics, Inc. | 2.12 Million USD | 80.047% |
| Sagimet Biosciences Inc. | 65 Thousand USD | -550.769% |
| PTC Therapeutics, Inc. | 415.02 Million USD | 99.898% |
| scPharmaceuticals Inc. | 40.26 Million USD | 98.95% |
| Fulcrum Therapeutics, Inc. | 10.82 Million USD | 96.091% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -180.132% |
| NLS Pharmaceutics AG | 1.63 Million USD | 74.109% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Akero Therapeutics, Inc. | 26.04 Million USD | 98.376% |
| Eliem Therapeutics, Inc. | 349 Thousand USD | -21.203% |
| Lisata Therapeutics, Inc. | 305 Thousand USD | -38.689% |
| Stoke Therapeutics, Inc. | 6.83 Million USD | 93.811% |
| Reneo Pharmaceuticals, Inc. | 973 Thousand USD | 56.526% |
| Outlook Therapeutics, Inc. | 35.55 Million USD | 98.81% |
| ProMIS Neurosciences, Inc. | - USD | -Infinity% |
| Daré Bioscience, Inc. | 5.31 Million USD | 92.046% |
| bluebird bio, Inc. | 330.32 Million USD | 99.872% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 99.963% |
| DBV Technologies S.A. | 14.38 Million USD | 97.059% |
| Avidity Biosciences, Inc. | 9.85 Million USD | 95.706% |
| Galecto, Inc. | 249 Thousand USD | -69.88% |
| Sensei Biotherapeutics, Inc. | 6.2 Million USD | 93.186% |
| Spruce Biosciences, Inc. | 4.6 Million USD | 90.822% |
| Inhibrx Biosciences, Inc. | 210.14 Million USD | 99.799% |
| GlycoMimetics, Inc. | 808.4 Thousand USD | 47.675% |
| Arcutis Biotherapeutics, Inc. | 205.91 Million USD | 99.795% |
| ADMA Biologics, Inc. | 141.41 Million USD | 99.701% |
| Clene Inc. | 32.16 Million USD | 98.685% |
| Recursion Pharmaceuticals, Inc. | 50.67 Million USD | 99.165% |
| Aptose Biosciences Inc. | 1 Million USD | 58.111% |
| ZyVersa Therapeutics, Inc. | 8656.00 USD | -4786.784% |
| Soligenix, Inc. | 3.49 Million USD | 87.895% |
| Century Therapeutics, Inc. | 48.17 Million USD | 99.122% |
| Kura Oncology, Inc. | 17.2 Million USD | 97.541% |
| Surrozen, Inc. | 3.37 Million USD | 87.482% |
| TScan Therapeutics, Inc. | 92.43 Million USD | 99.542% |
| Ocean Biomedical, Inc. | 2.15 Million USD | 80.326% |
| CytomX Therapeutics, Inc. | 13.97 Million USD | 96.973% |
| Autolus Therapeutics plc | 52.96 Million USD | 99.201% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| Eterna Therapeutics Inc. | 41.84 Million USD | 98.989% |
| Caribou Biosciences, Inc. | 27.48 Million USD | 98.461% |
| GRI Bio, Inc. | 14 Thousand USD | -2921.429% |
| Xenetic Biosciences, Inc. | - USD | -Infinity% |
| Janux Therapeutics, Inc. | 24.54 Million USD | 98.276% |
| INmune Bio, Inc. | 10.43 Million USD | 95.947% |
| Heron Therapeutics, Inc. | 179.62 Million USD | 99.765% |
| SAB Biotherapeutics, Inc. | 5.9 Million USD | 92.839% |
| Pasithea Therapeutics Corp. | 81.68 Thousand USD | -417.875% |
| Tenax Therapeutics, Inc. | 500.9 Thousand USD | 15.553% |
| Jaguar Health, Inc. | 35.86 Million USD | 98.82% |
| Entero Therapeutics, Inc. | 826.84 Thousand USD | 48.842% |
| Milestone Pharmaceuticals Inc. | 51.77 Million USD | 99.183% |
| Clearside Biomedical, Inc. | 43 Million USD | 99.016% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 99.269% |
| Coherus BioSciences, Inc. | 480.84 Million USD | 99.912% |
| Verastem, Inc. | 41.55 Million USD | 98.982% |
| Pliant Therapeutics, Inc. | 11.37 Million USD | 96.28% |
| Histogen Inc. | 4.62 Million USD | 90.848% |
| Aprea Therapeutics, Inc. | - USD | -Infinity% |
| ACADIA Pharmaceuticals Inc. | 57.2 Million USD | 99.261% |
| Surrozen, Inc. | 3.37 Million USD | 87.482% |
| Organovo Holdings, Inc. | 1.39 Million USD | 69.656% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Cadrenal Therapeutics, Inc. Common Stock | 21.35 Thousand USD | -1881.265% |
| Centessa Pharmaceuticals plc | 84.58 Million USD | 99.5% |
| Hepion Pharmaceuticals, Inc. | 209.02 Thousand USD | -102.373% |
| BioRestorative Therapies, Inc. | 162.31 Thousand USD | -160.601% |
| Kronos Bio, Inc. | 28.27 Million USD | 98.504% |
| Turnstone Biologics Corp. | 3.21 Million USD | 86.839% |
| Synaptogenix, Inc. | - USD | -Infinity% |
| Tiziana Life Sciences Ltd | 247 Thousand USD | -71.255% |
| Entrada Therapeutics, Inc. | 68.23 Million USD | 99.38% |
| Aurinia Pharmaceuticals Inc. | 97.6 Million USD | 99.567% |
| Exelixis, Inc. | 189.94 Million USD | 99.777% |
| Nurix Therapeutics, Inc. | 30.61 Million USD | 98.618% |
| Apellis Pharmaceuticals, Inc. | 110.92 Million USD | 99.619% |
| Jasper Therapeutics, Inc. | 2.78 Million USD | 84.817% |
| ESSA Pharma Inc. | 80.32 Thousand USD | -426.591% |
| TNF Pharmaceuticals, Inc. | 48.87 Thousand USD | -765.562% |
| Avid Bioservices, Inc. | 207.83 Million USD | 99.796% |
| Insmed Incorporated | 1.2 Billion USD | 99.965% |
| MediWound Ltd. | 6.71 Million USD | 93.697% |
| OmniAb, Inc. | 25.56 Million USD | 98.345% |
| Alector, Inc. | 38.91 Million USD | 98.913% |
| Seres Therapeutics, Inc. | 213.93 Million USD | 99.802% |
| Zai Lab Limited | 15.15 Million USD | 97.208% |
| AlloVir, Inc. | 27.42 Million USD | 98.458% |
| Revance Therapeutics, Inc. | 478.43 Million USD | 99.912% |
| ORIC Pharmaceuticals, Inc. | 10.21 Million USD | 95.858% |
| Aura Biosciences, Inc. | 19.55 Million USD | 97.837% |
| Immunic, Inc. | 1.33 Million USD | 68.291% |
| Tarsus Pharmaceuticals, Inc. | 31.73 Million USD | 98.667% |
| Veracyte, Inc. | 12.63 Million USD | 96.651% |
| InMed Pharmaceuticals Inc. | 644.86 Million USD | 99.934% |
| FibroGen, Inc. | 170.45 Million USD | 99.752% |
| SeaStar Medical Holding Corporation | 9.08 Million USD | 95.342% |
| Catalyst Pharmaceuticals, Inc. | 3.55 Million USD | 88.108% |
| Adial Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sonnet BioTherapeutics Holdings, Inc. | 203.91 Thousand USD | -107.443% |
| Cyclacel Pharmaceuticals, Inc. | 37 Thousand USD | -1043.243% |
| Amylyx Pharmaceuticals, Inc. | 4.23 Million USD | 90.017% |
| Fortrea Holdings Inc. | 1.67 Billion USD | 99.975% |
| KalVista Pharmaceuticals, Inc. | 7.31 Million USD | 94.219% |
| XBiotech Inc. | - USD | -Infinity% |
| Jasper Therapeutics, Inc. | 2.78 Million USD | 84.817% |
| Keros Therapeutics, Inc. | 14.44 Million USD | 97.071% |
| SELLAS Life Sciences Group, Inc. | 906 Thousand USD | 53.311% |
| Lyra Therapeutics, Inc. | 26.88 Million USD | 98.426% |
| Foghorn Therapeutics Inc. | 45.07 Million USD | 99.062% |
| Agenus Inc. | 350.24 Million USD | 99.879% |
| Y-mAbs Therapeutics, Inc. | 1.41 Million USD | 70.19% |
| Theravance Biopharma, Inc. | 45.23 Million USD | 99.065% |
| Ultragenyx Pharmaceutical Inc. | 43.16 Million USD | 99.02% |
| Metagenomi, Inc. Common Stock | 48.22 Million USD | 99.123% |
| BioCryst Pharmaceuticals, Inc. | 848.71 Million USD | 99.95% |
| Gain Therapeutics, Inc. | 1.02 Million USD | 58.828% |
| C4 Therapeutics, Inc. | 70.97 Million USD | 99.404% |
| Creative Medical Technology Holdings, Inc. | 14.19 Thousand USD | -2880.132% |
| Chemomab Therapeutics Ltd. | 392 Thousand USD | -7.908% |
| Lantern Pharma Inc. | 234.47 Thousand USD | -80.406% |
| Eledon Pharmaceuticals, Inc. | 383 Thousand USD | -10.444% |
| Ainos, Inc. | 5.96 Million USD | 92.907% |
| Pluri Inc. | 29.61 Million USD | 98.572% |
| Prothena Corporation plc | 11.83 Million USD | 96.426% |
| Adaptimmune Therapeutics plc | 25.23 Million USD | 98.324% |
| Rallybio Corporation | 392 Thousand USD | -7.908% |
| Kodiak Sciences Inc. | 181.63 Million USD | 99.767% |
| Cue Biopharma, Inc. | 14.69 Million USD | 97.121% |
| MeiraGTx Holdings plc | 89.26 Million USD | 99.526% |
| Annexon, Inc. | 31.35 Million USD | 98.651% |
| Assembly Biosciences, Inc. | 2.34 Million USD | 81.939% |
| Moderna, Inc. | - USD | -Infinity% |
| Cocrystal Pharma, Inc. | 1.85 Million USD | 77.172% |
| Cidara Therapeutics, Inc. | 4.87 Million USD | 91.327% |
| Blueprint Medicines Corporation | 774.12 Million USD | 99.945% |
| Immix Biopharma, Inc. | - USD | -Infinity% |
| CalciMedica, Inc. | - USD | -Infinity% |
| Monte Rosa Therapeutics, Inc. | 46.03 Million USD | 99.081% |
| Scholar Rock Holding Corporation | 61.81 Million USD | 99.316% |
| Wave Life Sciences Ltd. | 32.11 Million USD | 98.683% |
| Sana Biotechnology, Inc. | 104.09 Million USD | 99.594% |
| Elicio Therapeutics, Inc. | 6.91 Million USD | 93.885% |
| Adlai Nortye Ltd. American Depositary Shares | 31.54 Million USD | 98.659% |
| Nutriband Inc. | 241.28 Thousand USD | -75.311% |
| Protara Therapeutics, Inc. | 5.46 Million USD | 92.263% |
| Vor Biopharma Inc. | 35.66 Million USD | 98.814% |
| Roivant Sciences Ltd. | 499.74 Million USD | 99.915% |
| Alkermes plc | 290.73 Million USD | 99.855% |
| ProKidney Corp. | 4.41 Million USD | 90.415% |
| Applied Therapeutics, Inc. | 1.22 Million USD | 65.498% |
| Arcellx, Inc. | 97.62 Million USD | 99.567% |
| BridgeBio Pharma, Inc. | 1.73 Billion USD | 99.976% |
| Tango Therapeutics, Inc. | 38.92 Million USD | 98.913% |
| Galectin Therapeutics Inc. | 71.8 Million USD | 99.411% |
| Atai Life Sciences N.V. | 16.47 Million USD | 97.433% |
| Renovaro Biosciences Inc. | 2.45 Million USD | 82.742% |
| Aerovate Therapeutics, Inc. | 675 Thousand USD | 37.333% |
| MediciNova, Inc. | 215.92 Thousand USD | -95.9% |
| Praxis Precision Medicines, Inc. | 2.49 Million USD | 83.046% |
| Cardio Diagnostics Holdings, Inc. | 1.26 Million USD | 66.456% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 99.773% |
| Biomea Fusion, Inc. | 10.29 Million USD | 95.892% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Cullinan Oncology, Inc. | 3.59 Million USD | 88.217% |
| Geron Corporation | 85.89 Million USD | 99.508% |
| NRx Pharmaceuticals, Inc. | 9.16 Million USD | 95.383% |
| 4D Molecular Therapeutics, Inc. | 14.67 Million USD | 97.117% |
| Dyne Therapeutics, Inc. | 27.41 Million USD | 98.457% |
| Kiniksa Pharmaceuticals, Ltd. | 12.25 Million USD | 96.549% |
| Royalty Pharma plc | 6.13 Billion USD | 99.993% |
| Ventyx Biosciences, Inc. | 12.5 Million USD | 96.618% |
| Imunon, Inc. | 1.62 Million USD | 73.965% |
| BioAtla, Inc. | 2.46 Million USD | 82.805% |
| Allogene Therapeutics, Inc. | 95.12 Million USD | 99.555% |
| Larimar Therapeutics, Inc. | 5.54 Million USD | 92.373% |
| Mersana Therapeutics, Inc. | 33.83 Million USD | 98.75% |
| Structure Therapeutics Inc. | 5.45 Million USD | 92.243% |
| 89bio, Inc. | 27.1 Million USD | 98.44% |
| Kezar Life Sciences, Inc. | 18.93 Million USD | 97.766% |
| aTyr Pharma, Inc. | 15.09 Million USD | 97.198% |
| Aligos Therapeutics, Inc. | 11.13 Million USD | 96.202% |
| Viridian Therapeutics, Inc. | 21.04 Million USD | 97.99% |
| EyeGate Pharmaceuticals, Inc. | 326.49 Thousand USD | -29.559% |
| Akari Therapeutics, Plc | - USD | -Infinity% |
| Tevogen Bio Holdings Inc. | 1.63 Million USD | 74.077% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 99.972% |
| Lexicon Pharmaceuticals, Inc. | 106.06 Million USD | 99.601% |
| Liquidia Corporation | 3.5 Million USD | 87.925% |
| Entera Bio Ltd. | 390 Thousand USD | -8.462% |
| GH Research PLC | 343 Thousand USD | -23.324% |
| Vericel Corporation | 88.14 Million USD | 99.52% |
| Arbutus Biopharma Corporation | 8.72 Million USD | 95.15% |
| Xencor, Inc. | 83.43 Million USD | 99.493% |
| 60 Degrees Pharmaceuticals, Inc. | 172.67 Thousand USD | -144.972% |
| Pasithea Therapeutics Corp. | 81.68 Thousand USD | -417.875% |
| Coeptis Therapeutics Holdings, Inc. | 1.22 Million USD | 65.448% |
| Vaxcyte, Inc. | 29.22 Million USD | 98.553% |
| Xenon Pharmaceuticals Inc. | 10.9 Million USD | 96.12% |
| Vanda Pharmaceuticals Inc. | 9.4 Million USD | 95.502% |
| Lexaria Bioscience Corp. | 163.96 Thousand USD | -157.979% |
| Portage Biotech Inc. | 47 Thousand USD | -800.0% |
| Cardio Diagnostics Holdings, Inc. | 1.26 Million USD | 66.456% |
| Olema Pharmaceuticals, Inc. | 2.41 Million USD | 82.499% |
| OncoCyte Corporation | 2.86 Million USD | 85.256% |
| Qualigen Therapeutics, Inc. | 1.29 Million USD | 67.442% |
| Processa Pharmaceuticals, Inc. | 150.55 Thousand USD | -180.962% |
| Purple Biotech Ltd. | 351 Thousand USD | -20.513% |
| Tempest Therapeutics, Inc. | 20.66 Million USD | 97.953% |
| Sol-Gel Technologies Ltd. | 1.65 Million USD | 74.41% |
| Rhythm Pharmaceuticals, Inc. | 1.26 Million USD | 66.429% |
| CollPlant Biotechnologies Ltd. | 3.15 Million USD | 86.61% |
| Moleculin Biotech, Inc. | 574 Thousand USD | 26.307% |
| United Therapeutics Corporation | 700 Million USD | 99.94% |
| HilleVax, Inc. | 51.19 Million USD | 99.174% |
| Silo Pharma, Inc. | - USD | -Infinity% |
| Telomir Pharmaceuticals, Inc. Common Stock | 101 Thousand USD | -318.812% |
| Pharming Group N.V. | 171.54 Million USD | 99.753% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Genprex, Inc. | - USD | -Infinity% |
| Apogee Therapeutics, Inc. | 2.03 Million USD | 79.204% |
| Neumora Therapeutics, Inc. Common Stock | 5.23 Million USD | 91.914% |
| Pyxis Oncology, Inc. | 21.33 Million USD | 98.017% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| OKYO Pharma Limited | - USD | -Infinity% |
| Savara Inc. | 26.73 Million USD | 98.418% |
| Windtree Therapeutics, Inc. | 16.83 Million USD | 97.487% |
| Curis, Inc. | 2.79 Million USD | 84.86% |
| Carmell Therapeutics Corporation | 2.13 Million USD | 80.201% |
| Achieve Life Sciences, Inc. | 16.73 Million USD | 97.472% |
| BeiGene, Ltd. | 930.18 Million USD | 99.955% |
| Protagonist Therapeutics, Inc. | 1.14 Million USD | 62.927% |
| Erasca, Inc. | 55.85 Million USD | 99.243% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| Vincerx Pharma, Inc. | 2.5 Million USD | 83.094% |
| Fresh Tracks Therapeutics, Inc. | - USD | -Infinity% |
| Acrivon Therapeutics, Inc. Common Stock | 4.64 Million USD | 90.891% |
| Celldex Therapeutics, Inc. | 2.54 Million USD | 83.36% |
| Cogent Biosciences, Inc. | 18.85 Million USD | 97.756% |
| Adicet Bio, Inc. | 20.92 Million USD | 97.978% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 99.905% |
| Aditxt, Inc. | 18.21 Million USD | 97.678% |
| Adagene Inc. | 22.3 Million USD | 98.104% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 15.3 Million USD | 97.236% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 20.29 Million USD | 97.916% |
| Compugen Ltd. | 1.35 Million USD | 68.69% |
| Generation Bio Co. | 97.89 Million USD | 99.568% |
| Astria Therapeutics, Inc. | 329 Thousand USD | -28.571% |
| Black Diamond Therapeutics, Inc. | 25.29 Million USD | 98.328% |
| Invivyd, Inc. | 2.16 Million USD | 80.462% |
| Relay Therapeutics, Inc. | 53.46 Million USD | 99.209% |
| Quoin Pharmaceuticals, Ltd. | 3523.73 USD | -11904.325% |
| Spero Therapeutics, Inc. | 5.54 Million USD | 92.369% |
| Artelo Biosciences, Inc. | 63 Thousand USD | -571.429% |
| 2seventy bio, Inc. | 256.67 Million USD | 99.835% |
| Instil Bio, Inc. | 86.05 Million USD | 99.508% |
| Capricor Therapeutics, Inc. | 5.61 Million USD | 92.463% |
| Elevai Labs, Inc. Common Stock | 210.48 Thousand USD | -100.961% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Citius Pharmaceuticals, Inc. | 481.24 Thousand USD | 12.103% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| ALX Oncology Holdings Inc. | 17.19 Million USD | 97.54% |
| Vir Biotechnology, Inc. | 124.54 Million USD | 99.66% |
| Evaxion Biotech A/S | 10.86 Million USD | 96.108% |
| Ocular Therapeutix, Inc. | 83.38 Million USD | 99.493% |
| Verve Therapeutics, Inc. | 74.9 Million USD | 99.435% |
| Tyra Biosciences, Inc. | 6.49 Million USD | 93.488% |
| Cingulate Inc. | 3.13 Million USD | 86.508% |
| Galmed Pharmaceuticals Ltd. | 41 Thousand USD | -931.707% |
| Unity Biotechnology, Inc. | 26.99 Million USD | 98.433% |
| Connect Biopharma Holdings Limited | 465 Thousand USD | 9.032% |
| Clearmind Medicine Inc. | - USD | -Infinity% |
| Bolt Biotherapeutics, Inc. | 20.21 Million USD | 97.908% |
| CERo Therapeutics Holdings, Inc. | 1.55 Million USD | 72.797% |
| Viking Therapeutics, Inc. | 1.26 Million USD | 66.429% |
| Madrigal Pharmaceuticals, Inc. | 117.19 Million USD | 99.639% |
| ImmunityBio, Inc. | 883.67 Million USD | 99.952% |
| Korro Bio, Inc. | 33.2 Million USD | 98.726% |
| Kineta, Inc. | 1.31 Million USD | 67.882% |
| BioVie Inc. | 6.11 Million USD | 93.079% |
| Codexis, Inc. | 22.36 Million USD | 98.109% |
| Celularity Inc. | 65.41 Million USD | 99.353% |
| Aileron Therapeutics, Inc. | 91.45 Million USD | 99.537% |
| Crinetics Pharmaceuticals, Inc. | 51.72 Million USD | 99.182% |
| Virax Biolabs Group Limited | 224.3 Thousand USD | -88.587% |
| Cibus, Inc. | 24.62 Million USD | 98.282% |
| IN8bio, Inc. | 4.89 Million USD | 91.355% |
| Adverum Biotechnologies, Inc. | 75.03 Million USD | 99.436% |
| Avalo Therapeutics, Inc. | 3.9 Million USD | 89.162% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 99.971% |
| Eyenovia, Inc. | 16.1 Million USD | 97.374% |
| Puma Biotechnology, Inc. | 111.49 Million USD | 99.621% |
| Conduit Pharmaceuticals Inc. | 985 Thousand USD | 57.056% |
| Elevation Oncology, Inc. | 30.13 Million USD | 98.596% |
| Xilio Therapeutics, Inc. | 11.45 Million USD | 96.308% |
| Cardiff Oncology, Inc. | 2.14 Million USD | 80.316% |
| Enanta Pharmaceuticals, Inc. | 26.51 Million USD | 98.405% |
| Regulus Therapeutics Inc. | 3.1 Million USD | 86.364% |
| Moolec Science SA | 2.64 Million USD | 84.009% |
| Acumen Pharmaceuticals, Inc. | 28.48 Million USD | 98.515% |
| LAVA Therapeutics N.V. | 6.31 Million USD | 93.3% |
| Atea Pharmaceuticals, Inc. | 2.4 Million USD | 82.39% |
| Compass Therapeutics, Inc. | 1.73 Million USD | 75.591% |
| Greenwich LifeSciences, Inc. | - USD | -Infinity% |
| TFF Pharmaceuticals, Inc. | 115.25 Thousand USD | -267.015% |
| Humacyte, Inc. | 58.1 Million USD | 99.272% |
| PMV Pharmaceuticals, Inc. | 13.28 Million USD | 96.816% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Genelux Corporation | 2.51 Million USD | 83.208% |
| Trevi Therapeutics, Inc. | 1.33 Million USD | 68.386% |
| Notable Labs, Ltd. | 2.04 Million USD | 79.356% |
| Immunovant, Inc. | 138 Thousand USD | -206.522% |
| Quantum-Si incorporated | 15.3 Million USD | 97.236% |
| DiaMedica Therapeutics Inc. | 400 Thousand USD | -5.75% |
| Vera Therapeutics, Inc. | 53.7 Million USD | 99.212% |
| Acasti Pharma Inc. | - USD | -Infinity% |
| MiNK Therapeutics, Inc. | - USD | -Infinity% |
| Soleno Therapeutics, Inc. | 403 Thousand USD | -4.963% |
| PepGen Inc. | 20.1 Million USD | 97.896% |
| Nuvectis Pharma, Inc. | - USD | -Infinity% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Immuneering Corporation | 4.46 Million USD | 90.522% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Belite Bio, Inc | 886 Thousand USD | 52.257% |
| XOMA Corporation | 124.45 Million USD | 99.66% |
| ARS Pharmaceuticals, Inc. | 274 Thousand USD | -54.38% |
| Bionomics Limited | 239.61 Million USD | 99.823% |
| Alpha Tau Medical Ltd. | 13.27 Million USD | 96.814% |
| uniQure N.V. | 138.4 Million USD | 99.694% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | 85.42 Million USD | 99.505% |
| Forte Biosciences, Inc. | - USD | -Infinity% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Enlivex Therapeutics Ltd. | 1.03 Million USD | 59.012% |
| Conduit Pharmaceuticals Inc. | 985 Thousand USD | 57.056% |
| SeaStar Medical Holding Corporation | 9.08 Million USD | 95.342% |
| FibroBiologics, Inc. Common Stock | 1.74 Million USD | 75.787% |
| Altimmune, Inc. | 671 Thousand USD | 36.96% |
| LENZ Therapeutics, Inc. | 362 Thousand USD | -16.851% |
| Alpha Tau Medical Ltd. | 13.27 Million USD | 96.814% |
| Peak Bio, Inc. | 10.72 Million USD | 96.055% |
| Zevra Therapeutics, Inc. | 42.76 Million USD | 99.011% |
| Benitec Biopharma Inc. | 284 Thousand USD | -48.944% |
| Spyre Therapeutics, Inc. | 84.55 Million USD | 99.5% |
| NKGen Biotech, Inc. Common Stock | 19.92 Million USD | 97.877% |
| Zura Bio Limited | - USD | -Infinity% |
| PolyPid Ltd. | 11.77 Million USD | 96.409% |
| NKGen Biotech, Inc. Warrants | 19.92 Million USD | 97.877% |
| argenx SE | 20 Million USD | 97.885% |
| Immunome, Inc. | 1.65 Million USD | 74.364% |
| Verona Pharma plc | 51.32 Million USD | 99.176% |
| enGene Holdings Inc. Warrants | 9.77 Million USD | 95.674% |
| Shattuck Labs, Inc. | 4.2 Million USD | 89.933% |
| CervoMed Inc. | - USD | -Infinity% |
| Plus Therapeutics, Inc. | 4.18 Million USD | 89.883% |
| Dianthus Therapeutics, Inc. | 585 Thousand USD | 27.692% |
| Moolec Science SA | 2.64 Million USD | 84.009% |
| Enveric Biosciences, Inc. | - USD | -Infinity% |
| Design Therapeutics, Inc. | 3.05 Million USD | 86.131% |
| Leap Therapeutics, Inc. | 262 Thousand USD | -61.45% |
| Seelos Therapeutics, Inc. | 14.22 Million USD | 97.027% |
| Achilles Therapeutics plc | 4.61 Million USD | 90.834% |
| CERo Therapeutics Holdings, Inc. | 1.55 Million USD | 72.797% |
| CG Oncology, Inc. Common stock | 826 Thousand USD | 48.789% |
| Fractyl Health, Inc. Common Stock | 373.72 Million USD | 99.887% |
| Rani Therapeutics Holdings, Inc. | 30.09 Million USD | 98.595% |
| MoonLake Immunotherapeutics | 3.69 Million USD | 88.561% |
| Tourmaline Bio, Inc. | 415 Thousand USD | -1.928% |
| Beam Therapeutics Inc. | 173.17 Million USD | 99.756% |
| Mirum Pharmaceuticals, Inc. | 308.14 Million USD | 99.863% |
| AEON Biopharma, Inc. | 278 Thousand USD | -52.158% |
| Aadi Bioscience, Inc. | 7.02 Million USD | 93.978% |
| Enliven Therapeutics, Inc. | 335 Thousand USD | -26.269% |
| Kiora Pharmaceuticals, Inc. | 106.89 Thousand USD | -295.73% |
| NeurAxis, Inc. | 224.26 Thousand USD | -88.62% |
| Iovance Biotherapeutics, Inc. | 75.86 Million USD | 99.442% |
| Lumos Pharma, Inc. | 6.58 Million USD | 93.576% |
| Opiant Pharmaceuticals, Inc. | 17.08 Million USD | 97.523% |
| Palisade Bio, Inc. | 369 Thousand USD | -14.634% |
| Nutriband Inc. | 241.28 Thousand USD | -75.311% |
| Taysha Gene Therapies, Inc. | 61.1 Million USD | 99.308% |
| Neurogene Inc. | 16.25 Million USD | 97.398% |
| Kintara Therapeutics, Inc. | - USD | -Infinity% |
| CARGO Therapeutics, Inc. Common Stock | 28.54 Million USD | 98.518% |
| Athira Pharma, Inc. | 1.58 Million USD | 73.312% |
| HCW Biologics Inc. | 6.45 Million USD | 93.444% |
| XOMA Corporation | 124.45 Million USD | 99.66% |
| Nektar Therapeutics | 230.4 Million USD | 99.816% |
| Arvinas, Inc. | 3.4 Million USD | 87.559% |
| Tevogen Bio Holdings Inc. | 1.63 Million USD | 74.077% |
| Merus N.V. | 12.16 Million USD | 96.522% |
| Omega Therapeutics, Inc. | 128.42 Million USD | 99.671% |
| Quince Therapeutics, Inc. | 13.81 Million USD | 96.938% |
| Rezolute, Inc. | 2.22 Million USD | 81.014% |
| Clene Inc. | 32.16 Million USD | 98.685% |
| Indaptus Therapeutics, Inc. | 175.05 Thousand USD | -141.641% |
| BeyondSpring Inc. | 3.99 Million USD | 89.412% |
| Synlogic, Inc. | 17.27 Million USD | 97.551% |
| Allarity Therapeutics, Inc. | 1.3 Million USD | 67.462% |
| Phio Pharmaceuticals Corp. | 35 Thousand USD | -1108.571% |
| Peak Bio, Inc. | 10.72 Million USD | 96.055% |
| Werewolf Therapeutics, Inc. | 51.92 Million USD | 99.185% |
| Krystal Biotech, Inc. | 8.09 Million USD | 94.774% |
| Karyopharm Therapeutics Inc. | 177.01 Million USD | 99.761% |
| SpringWorks Therapeutics, Inc. | 7.05 Million USD | 94.006% |
| Lipella Pharmaceuticals Inc. | 136.59 Thousand USD | -209.677% |
| MannKind Corporation | 382.37 Million USD | 99.889% |
| Ikena Oncology, Inc. | 10.73 Million USD | 96.061% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 409 Thousand USD | -3.423% |
| Gossamer Bio, Inc. | 212.46 Million USD | 99.801% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | 174 Thousand USD | -143.103% |
| NRx Pharmaceuticals, Inc. | 9.16 Million USD | 95.383% |
| Legend Biotech Corporation | 328.67 Million USD | 99.871% |
| Mural Oncology plc | 15 Million USD | 97.182% |
| Disc Medicine, Inc. | 2.1 Million USD | 79.867% |
| Champions Oncology, Inc. | 7.43 Million USD | 94.307% |
| REGENXBIO Inc. | 89.29 Million USD | 99.526% |
| Ensysce Biosciences, Inc. | 854.69 Thousand USD | 50.509% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | 552.98 Thousand USD | 23.506% |
| Edgewise Therapeutics, Inc. | 5.41 Million USD | 92.187% |
| Vaxart, Inc. | 26.51 Million USD | 98.405% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | 15.65 Million USD | 97.298% |
| Cellectis S.A. | 92.85 Million USD | 99.544% |
| Longeveron Inc. | 2.04 Million USD | 79.275% |
| Repare Therapeutics Inc. | 3.41 Million USD | 87.595% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 99.97% |
| Inozyme Pharma, Inc. | 46.59 Million USD | 99.092% |
| Revolution Medicines, Inc. | 87.94 Million USD | 99.519% |
| Nymox Pharmaceutical Corporation | 173 Thousand USD | -144.509% |
| Third Harmonic Bio, Inc. | 3.95 Million USD | 89.299% |
| ArriVent BioPharma, Inc. Common Stock | 317 Thousand USD | -33.438% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 175 Thousand USD | -141.714% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 99.948% |
| Denali Therapeutics Inc. | 52.24 Million USD | 99.19% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Veru Inc. | 14.4 Million USD | 97.064% |
| Corvus Pharmaceuticals, Inc. | 1.37 Million USD | 69.214% |
| Cingulate Inc. | 3.13 Million USD | 86.508% |
| Passage Bio, Inc. | 26.29 Million USD | 98.391% |
| Context Therapeutics Inc. | - USD | -Infinity% |
| Exicure, Inc. | 6.66 Million USD | 93.653% |
| Day One Biopharmaceuticals, Inc. | 408 Thousand USD | -3.676% |
| Oramed Pharmaceuticals Inc. | 894 Thousand USD | 52.685% |
| Scinai Immunotherapeutics Ltd. | 20.56 Million USD | 97.943% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | 2.45 Million USD | 82.743% |
| Carisma Therapeutics, Inc. | 3.12 Million USD | 86.455% |
| Unicycive Therapeutics, Inc. | 811 Thousand USD | 47.842% |
| OmniAb, Inc. | 25.56 Million USD | 98.345% |
| Anew Medical, Inc. | 1.6 Million USD | 73.645% |
| Fennec Pharmaceuticals Inc. | 29.58 Million USD | 98.57% |
| Lipocine Inc. | 17.16 Thousand USD | -2364.173% |
| Lexeo Therapeutics, Inc. Common Stock | 11.63 Million USD | 96.365% |
| Nautilus Biotechnology, Inc. | 34.62 Million USD | 98.778% |
| SAB Biotherapeutics, Inc. | 5.9 Million USD | 92.839% |
| G1 Therapeutics, Inc. | 57.17 Million USD | 99.26% |
| Bellerophon Therapeutics, Inc. | 203 Thousand USD | -108.374% |
| Sage Therapeutics, Inc. | 5.16 Million USD | 91.81% |
| Ocugen, Inc. | 6.94 Million USD | 93.906% |
| Mind Medicine (MindMed) Inc. | 14.12 Million USD | 97.006% |
| Q32 Bio Inc. | 1.31 Million USD | 67.906% |
| Brainstorm Cell Therapeutics Inc. | 672 Thousand USD | 37.054% |
| Alumis Inc. Common Stock | 32.58 Million USD | 98.702% |
| Equillium, Inc. | 824 Thousand USD | 48.665% |
| Kyverna Therapeutics, Inc. | 9.07 Million USD | 95.341% |
| Coya Therapeutics, Inc. | - USD | -Infinity% |
| CNS Pharmaceuticals, Inc. | 300.8 Thousand USD | -40.622% |
| Dominari Holdings Inc. | 3.02 Million USD | 86.03% |
| Edesa Biotech, Inc. | 94.48 Thousand USD | -347.681% |
| vTv Therapeutics Inc. | 529 Thousand USD | 20.038% |
| Bio-Techne Corporation | 419.53 Million USD | 99.899% |
| Agios Pharmaceuticals, Inc. | 71.99 Million USD | 99.412% |
| Harmony Biosciences Holdings, Inc. | 193.56 Million USD | 99.781% |
| Prelude Therapeutics Incorporated | 16.88 Million USD | 97.495% |
| Candel Therapeutics, Inc. | 22.76 Million USD | 98.142% |
| iTeos Therapeutics, Inc. | 6.05 Million USD | 93.017% |
| Nkarta, Inc. | 88.33 Million USD | 99.521% |
| BioCardia, Inc. | 1.31 Million USD | 67.833% |
| Iterum Therapeutics plc | 19.5 Million USD | 97.832% |